Welcome to our dedicated page for Champions Oncolo SEC filings (Ticker: CSBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, collaboration revenue splits, and non-cash stock-based compensation crowd every Champions Oncology filing. If hunting through 200+ pages to track pipeline progress feels daunting, our AI-powered platform turns that complexity into clarity. StockTitan instantly converts dense SEC jargon into plain-English takeaways—perfect whether you need the latest Champions Oncology insider trading Form 4 transactions or want its Tumorgraft™ revenue breakout without decoding footnotes.
All core documents are here the moment they hit EDGAR. Skim an AI summary of the Champions Oncology annual report 10-K simplified, drill into a Champions Oncology quarterly earnings report 10-Q filing, or set alerts for every Champions Oncology Form 4 insider transactions real-time. Curious about sudden leadership changes? The next Champions Oncology 8-K material events explained will appear with context, showing how a new study read-out might shift revenue guidance.
Use cases our users rely on:
- Compare quarter-over-quarter R&D spend in seconds using Champions Oncology earnings report filing analysis.
- Monitor Champions Oncology executive stock transactions Form 4 before pivotal trial updates.
- Review the Champions Oncology proxy statement executive compensation to evaluate pay vs. performance.
- Save hours understanding Champions Oncology SEC documents with AI rather than parsing scientific appendices yourself.
No more manual searches—just comprehensive coverage, real-time updates, and expert insights that make Champions Oncology SEC filings explained simply.
Champions Oncology reported higher revenue but weaker profitability for the quarter ended October 31, 2025. Oncology revenue grew to $15,035,000 from $13,489,000, an 11.5% increase, driven mainly by pharmacology services, which rose to $14,515,000 from $12,498,000. TOS data license revenue contributed $157,000 versus none a year ago, while other TOS revenue declined to $363,000 from $991,000 as flow cytometry and SaaS activity fell.
Income from operations for the quarter declined to $185,000 from $732,000, and net income attributable to common shares was $268,000 versus $728,000, or $0.02 per diluted share compared with $0.05. For the six months, oncology revenue increased to $29,030,000, but results swung to a loss from operations of $342,000 and a net loss attributable to common shares of $169,000, compared with income of $2,061,000 and $2,041,000, respectively, a year earlier. Higher research and development, sales and marketing, and general and administrative expenses reflect investment in the company’s data licensing platform and its Corellia target-discovery subsidiary. Cash was $8,516,000 with negative operating cash flow of $1,135,000, yet management believes existing cash and expected cash flows can fund operations through at least December 2026.
Champions Oncology, Inc. filed a current report to disclose that on December 15, 2025 it issued a press release announcing its unaudited financial results for its second quarter ended October 31, 2025.
The press release is attached as Exhibit 99.1, and the company states that the financial information described under Item 2.02 is being furnished rather than filed, and will only be incorporated into other securities filings if specifically referenced.
Champions Oncology (CSBR)13,790 shares of common stock on November 5, 2025 at an exercise price of $6.8 per share. The option has a ten-year term expiring on November 5, 2035.
The award vests over twelve months in four tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. Following the grant, the reporting person holds 13,790 derivative securities directly.
Champions Oncology (CSBR) reported an insider equity grant on a Form 4. Director David Sidransky was awarded an option to purchase 21,216 shares on 11/05/2025 at an exercise price of $6.8 per share, expiring on 11/05/2035.
The filing lists the transaction code as A (grant). The option was acquired in direct ownership. Vesting is scheduled over twelve months, with tranches on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026. The option is exercisable over a ten‑year period.
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.
Champions Oncology (CSBR) insider activity: a director and 10% owner reported an award of derivative securities. On 11/05/2025, the reporting person acquired an option to purchase 25,460 shares of common stock at an exercise price of $6.80 per share, recorded as a Code A grant and held directly.
The options vest over twelve months in four dates—11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026—and are exercisable over ten years, with an expiration date of 11/05/2035.
Champions Oncology (CSBR) director reported a stock option grant. On 11/05/2025, the reporting person received 21,216 options to purchase common stock at an exercise price of $6.80 per share, with an expiration date of 11/05/2035.
The options vest over twelve months in four equal installments on Nov 5, 2025, Feb 5, 2026, May 5, 2026, and Aug 5, 2026. Following the transaction, 21,216 derivative securities were beneficially owned, reported as Direct (D) ownership.
Champions Oncology (CSBR)94,405 shares at $2.1 per share (transaction code M), acquiring the same number of common shares.
After the transaction, he reported 1,056,539 shares beneficially owned directly and 0 derivative securities remaining. The exercised option covered 94,405 underlying shares with a $2.1 exercise price.
Champions Oncology (CSBR) reported results from its October 16, 2025 Annual Meeting. All seven director nominees were elected for one-year terms. The strongest director support was for Scott R. Tobin with 9,722,734 votes for.
Stockholders ratified the appointment of EisnerAmper LLP as independent auditor with 10,659,115 votes for. The non-binding advisory vote on executive compensation was approved with 9,720,681 votes for. Broker non-votes totaled 931,779 for proposals requiring them.
FAQ
What is the current stock price of Champions Oncolo (CSBR)?
What is the market cap of Champions Oncolo (CSBR)?
